Evommune Announces $30 Million Private Placement

Evommune, Inc. (“Evommune” or the “Company”) (NYSE: EVMN), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that it has entered into a securities purchase agreement to sell 4,966,889 shares of its common stock to a select group of dedicated healthcare institutional investors in a private placement. The purchase price of each share of common stock is $6.04. Evommune anticipates the gross proceeds from the private placement to be approximately $30 million, before deducting any transaction-related expenses. The private placement is expected to close on or about November 6, 2026, subject to the satisfaction of customary closing conditions.

The financing includes participation from both new and existing institutional investors, including Adage Capital Partners, L.P., Balyasny Asset Management, Defilade Capital Management, OrbiMed, Squadron Capital Management and other fundamental healthcare dedicated funds.